Latest Information Update: 13 Jul 2016
At a glance
- Originator Sentrimed
- Class Antineoplastics; Lectins
- Mechanism of Action Membrane glycoprotein modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 13 Jul 2016 Preclinical trials in Cancer in USA (unspecified route)
- 13 Jul 2016 MASL is available for licensing as of 13 Jul 2016. http://www.sentrimed.com/